Literature DB >> 20617526

Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain.

Karin B Jensen1, Frank Petzke, Serena Carville, Peter Fransson, Hanke Marcus, Steven C R Williams, Ernest Choy, Yves Mainguy, Richard Gracely, Martin Ingvar, Eva Kosek.   

Abstract

OBJECTIVE: Mood disturbance is common among patients with fibromyalgia (FM), but the influence of psychological symptoms on pain processing in this disorder is unknown. We undertook the present study to investigate the differential effect of depressive symptoms, anxiety, and catastrophizing on 1) pain symptoms and subjective ratings of general health status and 2) sensitivity to pain and cerebral processing of pressure pain.
METHODS: Eighty-three women (mean ± SD age 43.8 ± 8.1 years) who fulfilled the American College of Rheumatology 1990 criteria for the classification of FM participated in the study. Patients rated pain intensity (100-mm visual analog scale [VAS]), severity of FM (Fibromyalgia Impact Questionnaire), general health status (Short Form 36), depressive symptoms (Beck Depression Inventory), anxiety (State-Trait Anxiety Inventory), and catastrophizing (Coping Strategies Questionnaire). Experimental pain in the thumb was induced using a computer-controlled pressure stimulator. Event-related functional magnetic resonance imaging was performed during administration of painful stimuli representing 50 mm on a pain VAS, as well as nonpainful pressures.
RESULTS: A correlation analysis including all self-ratings showed that depressive symptoms, anxiety, and catastrophizing scores were correlated with one another (P < 0.001), but did not correlate with ratings of clinical pain or with sensitivity to pressure pain. However, the subjective rating of general health was correlated with depressive symptoms and anxiety (P < 0.001). Analyses of imaging results using self-rated psychological measures as covariates showed that brain activity during experimental pain was not modulated by depressive symptoms, anxiety, or catastrophizing.
CONCLUSION: Negative mood in FM patients can lead to a poor perception of one's physical health (and vice versa) but does not influence performance on assessments of clinical and experimental pain. Our data provide evidence that 2 partially segregated mechanisms are involved in the neural processing of experimental pain and negative affect.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2010        PMID: 20617526     DOI: 10.1002/art.27649

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  [Etiology and pathophysiology of fibromyalgia syndrome].

Authors:  C Sommer; W Häuser; M Burgmer; R Engelhardt; K Gerhold; F Petzke; T Schmidt-Wilcke; M Späth; T Tölle; N Uçeyler; H Wang; A Winkelmann; K Thieme
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

2.  Treatment-related changes in brain activation in patients with fibromyalgia syndrome.

Authors:  Martin Diers; Pinar Yilmaz; Mariela Rance; Kati Thieme; Richard H Gracely; Claudia Rolko; Marcus T Schley; Ulrike Kiessling; Haili Wang; Herta Flor
Journal:  Exp Brain Res       Date:  2012-03-17       Impact factor: 1.972

Review 3.  Monotherapy or combination therapy for fibromyalgia treatment?

Authors:  Elena Pita Calandre; Fernando Rico-Villademoros; Carmen María Rodríguez-López
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

4.  Differential efficiency of transcutaneous electrical nerve stimulation in dominant versus nondominant hands in fibromyalgia: placebo-controlled functional near-infrared spectroscopy study.

Authors:  Aykut Eken; Murat Kara; Bora Baskak; Ayşegül Baltacı; Didem Gökçay
Journal:  Neurophotonics       Date:  2017-09-05       Impact factor: 3.593

Review 5.  Neuroimaging of Central Sensitivity Syndromes: Key Insights from the Scientific Literature.

Authors:  Brian Walitt; Marta Ceko; John L Gracely; Richard H Gracely
Journal:  Curr Rheumatol Rev       Date:  2016

Review 6.  The role of antipsychotics in the management of fibromyalgia.

Authors:  Elena P Calandre; Fernando Rico-Villademoros
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

7.  Association of different levels of depressive symptoms with symptomatology, overall disease severity, and quality of life in women with fibromyalgia.

Authors:  Alberto Soriano-Maldonado; Kirstine Amris; Francisco B Ortega; Víctor Segura-Jiménez; Fernando Estévez-López; Inmaculada C Álvarez-Gallardo; Virginia A Aparicio; Manuel Delgado-Fernández; Marius Henriksen; Jonatan R Ruiz
Journal:  Qual Life Res       Date:  2015-06-14       Impact factor: 4.147

8.  Involvement of Oxidative Stress and Nerve Growth Factor in Behavioral and Biochemical Deficits of Experimentally Induced Musculoskeletal Pain in Mice: Ameliorative Effects of Heraclin.

Authors:  Anudeep Kaur; Lovedeep Singh; Saweta Garg; Harmanpreet Kaur; Nirmal Singh; Rajbir Bhatti
Journal:  J Mol Neurosci       Date:  2020-07-16       Impact factor: 3.444

9.  Profiles in fibromyalgia: algometry, auditory evoked potentials and clinical characterization of different subtypes.

Authors:  Yolanda Triñanes; Alberto González-Villar; Claudio Gómez-Perretta; María T Carrillo-de-la-Peña
Journal:  Rheumatol Int       Date:  2014-04-11       Impact factor: 2.631

10.  Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain.

Authors:  Karin B Jensen; Priti Srinivasan; Rosa Spaeth; Ying Tan; Eva Kosek; Frank Petzke; Serena Carville; Peter Fransson; Hanke Marcus; Steven C R Williams; Ernest Choy; Olivier Vitton; Richard Gracely; Martin Ingvar; Jian Kong
Journal:  Arthritis Rheum       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.